早期[68]Ga-PSMA-11 PET显像提高生化复发前列腺癌患者局部复发检出率
该研究回顾性分析203例生化复发前列腺癌患者,比较注射[68]Ga-PSMA-11后早期静态骨盆显像(中位283秒)与60分钟全身PET/CT对局部复发的检出率。早期显像检出率显著高于60分钟显像(24.6% vs 12.8%,p<0.001),且不确定发现显著减少(4.5% vs 15.8%,p<0.001)。作者建议早期PET采集应尽早开始(约5分钟),以避免膀胱放射性干扰。
要点
- 早期[68]Ga-PSMA-11 PET显像局部复发检出率高于60分钟显像(24.6% vs 12.8%,p<0.001)。
- 早期显像使不确定发现从15.8%降至4.5%(p<0.001)。
- 早期显像应尽早开始(约5分钟),以避免膀胱放射性干扰。
核心结论
- 在60分钟全身PET/CT基础上加做早期[68]Ga-PSMA-11 PET显像可提高生化复发前列腺癌患者局部复发的检出率。
- 作者建议早期PET采集应尽早开始(约5分钟),以避免后期出现的膀胱放射性干扰。
研究设计与样本
- 回顾性分析203例因生化失败转诊行[68]Ga-PSMA-11 PET/CT的连续前列腺癌患者,中位PSA值1.44 ng/ml。
- 除注射后60分钟全身PET/CT外,加做骨盆早期静态显像,中位开始时间283秒(范围243-491秒)。
- 基于视觉分析和病灶SUVmax计算进行评估。
主要发现
- 60分钟PET显像判定局部复发阳性26例(12.8%),中位SUVmax 10.8(范围4.7-40.9)。
- 早期PET显像提示局部复发50例(24.6%),中位SUVmax 5.9(范围2.9-17.6),检出率显著升高(p<0.001)。
- 60分钟PET显像的不确定发现在早期显像辅助下显著减少(15.8% vs 4.5%的患者,p<0.001)。
- 早期显像中63例(31.0%)可见膀胱放射性,中位SUVmax 8.2;有膀胱活性组与无膀胱活性组的早期采集开始时间差异显著(中位321 vs 275秒;范围281-491 vs 243-311秒;p<0.001)。
- 早期显像提示局部复发病灶的中位SUVmax显著高于臀肌、腹股沟血管和精囊/吻合口(5.9 vs 1.9、4.0和2.4)。
临床怎么用
- 作者建议在[68]Ga-PSMA-11 PET/CT中加做早期显像以提高局部复发检出率。
- 作者建议早期PET采集应尽早开始(约5分钟),以避免膀胱放射性干扰。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PET/CT using 68Ga-labelled prostate-specific membrane antigen PSMA-11 (HBEDD-CC) has emerged as a promising imaging method in the diagnostic evaluation of prostate cancer (PC) patients with biochemical recurrence. However, assessment of local recurrence (LR) may be limited by intense physiologic tracer accumulation in the urinary bladder on whole-body scans, normally conducted 60 min post-tracer injection (p.i.). It could be shown on early dynamic imaging studies that 68Ga-PSMA-11 uptake in PC lesions occurs earlier than tracer accumulation in the urinary bladder. This study aims to investigate whether early static PET acquisition increases detection rate of local recurrence on 68Ga-PSMA-11 PET/CT in comparison to PET imaging 60 min p.i.. METHODS: 203 consecutive PC patients with biochemical failure referred to 68Ga-PSMA-11 PET/CT were analysed retrospectively (median prostate specific antigen (PSA) value: 1.44 ng/ml). In addition to whole-body PET/CT scans 60 min p.i., early static imaging of the pelvis was performed, starting at a median time of 283 s p.i. (range: 243-491 s). Assessment was based on visual analysis and calculation of maximum standardized uptake value (SUVmax) of pathologic lesions present in the pelvic area found on early PET imaging and on 60 min-PET scans. RESULTS: 26 patients (12.8%) were judged positive for LR on PET scans 60 min p.i. (median SUVmax: 10.8; range: 4.7-40.9), whereas 50 patients (24.6%) revealed a lesion suggestive of LR on early PET imaging (median SUVmax: 5.9; range: 2.9-17.6), resulting in a significant rise in detection rate (p < 0.001). Equivocal findings on PET scans 60 min p.i. decreased significantly with the help of early imaging (15.8% vs. 4.5% of patients; p < 0.001). Tracer activity in the urinary bladder with a median SUVmax of 8.2 was present in 63 patients on early PET scans (31.0%). However, acquisition starting time of early PET scans differed significantly in the patient groups with and without urinary bladder activity (median starting time of 321 vs. 275 s p.i.; range: 281-491 vs. 243-311 s p.i.; p < 0.001). Median SUVmax value of lesions suggestive of LR on early images was significantly higher in comparison to gluteal muscle, inguinal vessels and seminal vesicle/anastomosis (median SUVmax: 5.9 vs. 1.9, 4.0 and 2.4, respectively). CONCLUSIONS: Performance of early imaging in 68Ga-PSMA-11 PET/CT in addition to whole-body scans 60 min p.i. increases the detection rate of local recurrence in PC patients with biochemical recurrence. Acquisition of early PET images should be started as early as 5 min p.i. in order to avoid disturbing tracer activity in the urinary bladder occuring at a later time point.
引用
- Uprimny C, Kroiss AS, Fritz J, et al. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. Eur J Nucl Med Mol Imaging. 2017. PMID: 28589253. doi:10.1007/s00259-017-3743-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。